Compare · PEN vs SYK
PEN vs SYK
Side-by-side comparison of Penumbra Inc. (PEN) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PEN and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 8.9x PEN ($12.65B).
- SYK has been more active in the news (8 items in the past 4 weeks vs 2 for PEN).
- Both have 25 recent analyst ratings on file.
- Company
- Penumbra Inc.
- Stryker Corporation
- Price
- $320.99-0.09%
- $294.69+0.46%
- Market cap
- $12.65B
- $112.48B
- 1M return
- -
- +5.16%
- 1Y return
- -
- -21.34%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 2
- 8
- Recent ratings
- 25
- 25
Penumbra Inc.
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest PEN
- SEC Form 4 filed by Penumbra Inc.
- New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
- President Narayan Shruthi covered exercise/tax liability with 1,230 shares, decreasing direct ownership by 4% to 32,650 units (SEC Form 4) to satisfy withholding obligation
- President Narayan Shruthi was granted 3,060 shares, increasing direct ownership by 10% to 33,880 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Penumbra Inc.
- SEC Form 10-Q filed by Penumbra Inc.
- Penumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Penumbra, Inc. Reports Second Quarter 2026 Financial Results
- THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
- First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)